Whalesbook
Zydus Lifesciences Par Brokerage ka Kya Hai Plan?
Motilal Oswal ne Zydus Lifesciences ke liye FY27 aur FY28 ki earnings ko lekar optimistic outlook dikhaya hai. Iska reason hai US products ki zabardast performance, especially jahaan competition kam hai, aur domestic market mein bhi company ne kamaal kiya hai. Brokerage ne R&D aur marketing mein ki gayi mehnat ko bhi growth ka bada factor maana hai.
Future Growth ka Valuation
Motilal Oswal ne Zydus Lifesciences ke liye naya target price ₹1,080 set kiya hai. Ye target 21x ke forward earnings multiple par based hai, jo FY26 se FY28 tak 7% ki earnings CAGR project karta hai. Brokerage ne FY27 ke liye earnings estimate 5% aur FY28 ke liye 4% badha diya hai. Lekin, Neutral rating maintain ki hai kyunki current stock price par zyada bada jump expect nahi hai.
Competition aur Market Trends
Pharma industry mein Zydus Lifesciences kaafi tagde competitors jaise Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, aur Cipla ke saath compete kar rahi hai. Indian pharma market saalana 11.26% se grow hone ka estimate hai 2025 se 2035 tak. Zydus US mein apne specialty portfolio ko expand karne ke liye acquisitions aur licensing strategies use kar rahi hai, saath hi medical devices aur diagnostics mein bhi diversify kar rahi hai. US generics market par bhi focus hai aur exclusive product launches ki planning hai. Domestic business bhi naye products aur strong therapy areas ki wajah se market se achha perform kar raha hai. Complex products jaise injectables, biosimilars, aur vaccines development mein R&D par bhi kafi investment ho rahi hai.
Potential Risks: Valuation aur Margins?
Sab achha hone ke bawajood, kuch risks bhi hain. Analysts ka kehna hai ki Zydus Lifesciences ka current valuation thoda stretched ho sakta hai. Kuch reports ke according, stock apne intrinsic value se 25% overvalued ho sakta hai. Haalanki Q4 FY26 mein company ne record sales aur margins report kiye hain, par future US sales ko lekar concerns hain kyuki competition badh rahi hai aur prices kam ho sakti hain. High R&D investments bhi costs badha rahe hain. Indian pharma sector generally US mein price erosion aur regulatory pressures jaise challenges face karta hai.
Outlook aur Projections
Motilal Oswal ko lagta hai ki Zydus Lifesciences FY26 se FY28 tak 7% earnings CAGR achieve karegi. North America mein company high single-digit growth expect kar rahi hai aur FY27 mein Indian market ko 200 se 400 basis points se outperform karegi. International markets mein bhi strong growth momentum continue hone ka chance hai, aur consumer segment mein double-digit growth expected hai. Margins 24% se upar rehne ki umeed hai, agar R&D expense 8% assume kiya jaaye toh.